On May 13, Innovo Therapeutics (Innovo Therapeutics, referred to as “Innovo”) recently announced the completion of an angel round of financing of nearly 100 million yuan, led by Juming Venture Capital, co-led by Chengyi Capital, and Alliance Ventures and Jiangsu Industrial Research Institute followed suit. This round of financing will be mainly used for the expansion and application of two targeted protein degradation platforms, and to promote the research and development of multiple tumor and tumor immune drug pipelines. In addition, the company has recently acquired global rights to an acute myeloid leukemia (AML) pipeline, which it plans to advance to clinical trials in 2023.
As a Sino-US joint venture anti-cancer drug research and development company, Innokang was established in June 2021. The company’s core management team has decades of successful drug research and development experience, especially in the field of targeted protein degradation. The main leading members of the Yinuokang team have respectively led PROTAC and molecular glue projects in new drug research and development companies in the United States, and promoted related drugs into clinical practice.
media coverage
Yioutou China Net Investment Community
Related events
- Yinuokang completes nearly 100 million yuan in angel round financing2022-05-13
- Biopharmaceutical company Gretson completes tens of millions of yuan in Series A financing2022-05-12
- Yudao Bio announced the completion of $40 million A+ round of financing2022-03-14
- Gerber Biotech completed nearly $50 million in Series A financing2022-03-01
- Eusen Jianheng completes 200 million yuan in Series A financing2022-02-08
This article is reproduced from: https://readhub.cn/topic/8fYx9Roy6rb
This site is for inclusion only, and the copyright belongs to the original author.